肝爽颗粒联合阿德福韦酯治疗肝纤维化的疗效分析

目的观察肝爽颗粒抗肝纤维化的疗效。方法选取本院2010年7月-2013年1月收治的68例慢性乙型肝炎肝硬化患者,分为试验组和对照组,每组34例。2组患者均治疗12个月,在单独使用阿德福韦酯治疗6个月后,试验组同时使用肝爽颗粒6个月,而对照组不用肝爽颗料。观察比较2组患者治疗前后肝纤维化血清指标:透明质酸(HA),层粘连蛋白(LN),Ⅳ型胶原(CⅣ),Ⅲ前胶原(PCⅢ)水平及肝脏硬度指标的变化。治疗前后比较采用配对t检验。结果试验组治疗前后血清HA、LN、CⅣ和PCⅢ值分别下降37.5%、34.2%、35.4%和39.9%,肝硬度值下降40.6%,治疗前后差异有统计学意义(t=2.238、2.151、2.148、2.189、2.189,P均0.05),而对照组治疗前后上述指标差异无统计学意义。结论肝爽颗粒可改善乙型肝炎肝硬化患者血清肝纤维化标志物水平及降低肝硬度值,表明其有抗肝纤维化疗效。

Therapeutic efficacy of Ganshuang granules in treatment of hepatic fibrosis

Objective To observe the therapeutic efficacy of Ganshuang granules in the treatment of hepatic fibrosis. Methods Sixty - eight patients with cirrhosis due to chronic hepatitis B （CHB） were divided into experimental group （n = 34） and control group （n = 34）. Both groups received adefovir dipivoxil for 6 months, and the experimental group received Ganshuang granules additionally for 24 weeks. After treatment, the changes in hepatic fibrosis indices including hyaluronic acid （HA）, laminin （LN）, collagen IV （C IV）, and precollagen III （PC III）, as well as liver stiffness value were evaluated by paired t test. Results In the experimental group, the serum levels of HA, LN, C IV, and PC HI were significantly decreased by 37.5%, 34.2%, 35.4%, and 39.9%, respectively （t = 2.238, 2. 151, 2. 148, and 2. 198, P 〈 0. 05 for all）, and the liver stiffness value was significantly cut by 40.6% （ t = 2. 189, P 〈 0.05 ）. However, the control group showed no significant changes in these indices. Conclusion For patients with cirrhosis due to CHB, Ganshuang granules can effectively reduce serum markers of hepatic fibrosis and liver stiffness value and have a good therapeutic efficacy in the treatment of hepatic fibrosis.